Even though the overall uptake of cardioprotective antihyperglycemic drugs has increased as second-line treatments for Type 2 diabetes mellitus, over the last decade, patients who actually have cardiovascular disease were less likely to be prescribed them compared to those without CVD.
While some guidelines recommend statin use to achieve low-density lipoprotein cholesterol (LDL-C) goal under 70 mg/dL for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients at higher risk, others recommend against a target LDL-C level.
How do demographic, social and geographic factors affect glycemic control over time in veterans newly diagnosed with diabetes?
How diabetes affects the prognosis of advanced prostate cancer (PC) is not well documented, according to a new study which sought to provide more information.
In patients with Type 2 diabetes mellitus, cardiorespiratory fitness and body mass index (BMI) play a role in statin-related progression to insulin therapy, according to a recent study.
Diabetes patients who are treated with anti-vascular endothelial growth factor (VEGF) injections, the primary treatment for diabetic retinopathy, have a higher likelihood of experiencing adverse events, such as acute myocardial infarction, cardiovascular disease or kidney disease, according to a recent study.
In 2020, in its annual revision of the Standards of Medical Care in Diabetes, the American Diabetes Association (ADA) made some significant changes in recommendations.
During the COVID-19 pandemic, high-risk diabetes patients who were treated in the VA Healthcare System adhered to their diabetes medication regimens and maintained high primary care use, even though virtual care replaced in-person care, according to a recent study.
While news reports focus on high demand for glucagon-like peptide-1 receptor agonists (GLP-1 RA), the real story might be widespread under use of those agents and others that reduce the risk of cardiovascular disease and chronic kidney disease progression in patients with Type 2 diabetes.
Concerns have been raised about GLP-1 receptor agonists causing unintended weight loss in older adults. A new VA study has put that worry to rest, finding no significant difference in weight loss with semaglutide use among veterans 65 or older compared to those who are younger. The authors concluded that age does not appear to be a “robust predictor” of semaglutide’s effect on weight.
Cardiorespiratory fitness (CRF) can be a good predictor of chronic disease. The problem is the difficulty and impracticability of routinely measuring that in primary care settings.
What is the association between cardiac autonomic neuropathy (CAN) with incident stroke among diabetes mellitus patients?
Individualizing hemoglobin A1c treatment goals in older adults is important to balance risks in benefits, according to a new study.
An estimated 1 in 10 Americans and 1 in 4 veterans has diabetes, not only putting them at increased risk for problems such as heart and kidney disease, but also making them more prone to complications such as infection and bleeding following surgery.
Metformin is recommended as first-line therapy for Type 2 diabetes at the VA and elsewhere. Among the benefits, according to the VA PBM, is that the drug, which has been in use for decades, is low-cost and safe to initiate in most patients, even those with moderate renal dysfunction.
When Mary Julius was diagnosed with Type 1 diabetes in 1974, the world was a very different place. There were only approximately 4.5 million Americans who had been diagnosed with diabetes.
Even though novel therapies for type 2 diabetes have been proven to reduce the risk of cardiovascular disease and chronic kidney disease progression, VHA prescription rates remain low.
Clinicians treating Type 2 diabetes have an arsenal of medications to help lower glucose levels in patients with uncontrolled blood sugar. The key question regards which work best to lower glucose levels and keep them low.
Using the VA’s Million Veteran Program data, a new study has determined that a diabetes genetic risk score is associated with all-cause dementia and clinically diagnosed vascular dementia in veterans.
How did a novel approach to provide diabetes specialty team care to rural veterans with Type 2 diabetes (T2DM) affect clinical outcomes and processes of care?
Not many studies have looked at the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, on preventing microvascular and cardiovascular disease outcomes in Type 2 diabetes.
Optimal diabetes management requires striking a careful balance. Over time, high blood glucose levels impair cardiovascular function, leading to delayed wound healing, heart disease and elevated risk of stroke.
One size doesn’t fit all, even when it comes to deciding which Type 2 diabetes patients would derive cardiovascular benefit from intensive glycemic control.
While it has been obvious for some time that the COVID-19 pandemic would create longer-term health effects, it is only now becoming clearer what some of those might be.
Cardiovascular disease is the No. 1 cause of death for women in the United States, and female veterans are at particular risk.
Diabetes affects one in four veterans—a rate more than double that of the general population. In an effort to improve glycemic control among veterans with diabetes the VA involves clinical pharmacy specialists (CPSs) in medication management, a strategy that has proven beneficial in a studies at a number of centers.
A recent review noted that ketogenic diets, which generally are very low in carbohydrate and very high in fat, have traditionally been employed to treat epileptic disorders, although they have been touted as a therapy for Type 2 diabetes and a range of other health conditions—neurodegenerative diseases, cancer, obesity, heart failure and nonalcoholic fatty liver disease (NAFLD).
Diabetes affects more than 34 million—or nearly 10% of—Americans and is the seventh-leading cause of death in the U.S. The prevalence is even higher among U.S. veterans; approximately 25% of individuals who’ve served in the military have diabetes.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a relatively new class of antihyperglycemics, have become an important tool in the treatment of Type 2 diabetes—a disease that affects an estimated 25% of VA patients.
Intensive glycemic control (INT) does not appear to have a protective effect when it comes to required eye procedures in patients with advanced diabetes.